CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

CD36, identified more than a quarter of a century ago as a platelet integral membrane glycoprotein (glycoprotein IV), was until recently best known as a receptor for thrombospondin-1 (TSP-1). TSP-1 is found in ECMs and platelet α granules, and it participates in cell attachment, motility, and proliferation, as well as in modulation of protease activity, TGF-β activation, neurite outgrowth, and angiogenesis (1). Initially, this receptor-ligand pair was shown to mediate interactions between platelets and monocytes, tumor cells, and matrix. Since then, CD36 has been implicated in multiple biological processes that define it as a multiligand scavenger receptor (see ref. 2 for review). These ligands appear remarkably diverse: In addition to TSP-1, they include long-chain fatty acids, modified LDL, retinal photoreceptor outer segments, Plasmodium falciparum malaria-parasitized erythrocytes, sickle erythrocytes, anionic phospholipids, apoptotic cells, and collagens I and IV. The biology of CD36 can be broadly divided in terms of functions that it mediates with or without TSP-1, but it is probable that it acts in concert with other proteins, such as fatty acid–binding proteins, caveola-associated proteins, integrins, cytoskeletal proteins, and signaling molecules, to effect its diverse functions.

[1]  K. Kain,et al.  Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance. , 2000, Blood.

[2]  M. Lagueux,et al.  Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells. , 1996, Immunity.

[3]  James Scott,et al.  Population genetics: Malaria susceptibility and CD36 mutation , 2000, Nature.

[4]  T. Willson,et al.  Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.

[5]  A. Bonen,et al.  Muscle-specific Overexpression of FAT/CD36 Enhances Fatty Acid Oxidation by Contracting Muscle, Reduces Plasma Triglycerides and Fatty Acids, and Increases Plasma Glucose and Insulin* , 1999, The Journal of Biological Chemistry.

[6]  R. Silverstein,et al.  Identification of a CD36-related Thrombospondin 1–binding Domain in HIV-1 Envelope Glycoprotein gp120: Relationship to HIV-1–specific Inhibitory Factors in Human Saliva , 1998, The Journal of experimental medicine.

[7]  Roy L. Silverstein,et al.  CD36 and atherosclerosis , 2000, Current opinion in lipidology.

[8]  C. Meldrum,et al.  Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. , 1996, The Biochemical journal.

[9]  M. Krieger,et al.  Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. , 2001, The Journal of clinical investigation.

[10]  P. Grimaldi,et al.  Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. , 1993, The Journal of biological chemistry.

[11]  R. F. Cook,et al.  Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease , 1994, The Journal of cell biology.

[12]  K. Nakajima,et al.  Absent myocardial iodine-123-BMIPP uptake and platelet/monocyte CD36 deficiency. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  T. Sugihara,et al.  Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. , 1992, Blood.

[14]  S. Gordon,et al.  Is the class A macrophage scavenger receptor (SR-A) multifunctional? - The mouse's tale. , 2001, The Journal of clinical investigation.

[15]  M. Krieger,et al.  The other side of scavenger receptors: pattern recognition for host defense , 1997, Current opinion in lipidology.

[16]  N. Hogg,et al.  Macrophage vitronectin receptor, CD36, and thrombospondin cooperate in recognition of neutrophils undergoing programmed cell death. , 1991, Chest.

[17]  M. Alessio,et al.  CD36 is a ditopic glycoprotein with the N-terminal domain implicated in intracellular transport. , 2000, Biochemical and biophysical research communications.

[18]  P. Grimaldi,et al.  Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.

[19]  S. Ryeom,et al.  CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium. , 1996, Journal of cell science.

[20]  K. Turley The challenge of pulmonary hypertension. , 1991, Chest.

[21]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[22]  J. Barnwell,et al.  Analysis of CD36 binding domains: ligand specificity controlled by dephosphorylation of an ectodomain. , 1993, Science.

[23]  S. Hazen,et al.  Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. , 2000, The Journal of clinical investigation.

[24]  James Scott,et al.  Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats , 1999, Nature Genetics.

[25]  David W. Dawson,et al.  CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.

[26]  Brian Seed,et al.  CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes , 1989, Cell.

[27]  E. Dennis,et al.  Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[29]  R. Silverstein,et al.  Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. , 2001, The Journal of clinical investigation.

[30]  A. Gotto,et al.  Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. , 2000, Journal of lipid research.

[31]  R. Silverstein,et al.  A Null Mutation in Murine CD36 Reveals an Important Role in Fatty Acid and Lipoprotein Metabolism* , 1999, The Journal of Biological Chemistry.

[32]  Josephine C. Adams,et al.  The Thrombospondin Gene Family , 1995 .

[33]  D. Steinberg Oxidative Modification of LDL and Atherogenesis , 1998 .

[34]  E. Dennis,et al.  Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[36]  A. Rusiñol,et al.  Isolation of a Somatic Cell Mutant Resistant to the Induction of Apoptosis by Oxidized Low Density Lipoprotein* , 2000, The Journal of Biological Chemistry.

[37]  L. Stanton,et al.  CD36 is a receptor for oxidized low density lipoprotein. , 1993, The Journal of biological chemistry.

[38]  A. Gotto,et al.  Transforming Growth Factor-β1 (TGF-β1) and TGF-β2 Decrease Expression of CD36, the Type B Scavenger Receptor, through Mitogen-activated Protein Kinase Phosphorylation of Peroxisome Proliferator-activated Receptor-γ* , 2000, The Journal of Biological Chemistry.

[39]  M. Wilcox,et al.  A Drosophila gene encoding an epithelial membrane protein with homology to CD36/LIMP II. , 1993, Journal of molecular biology.

[40]  I. Yuhanna,et al.  High Density Lipoprotein Prevents Oxidized Low Density Lipoprotein-induced Inhibition of Endothelial Nitric-oxide Synthase Localization and Activation in Caveolae* , 2000, The Journal of Biological Chemistry.

[41]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[43]  Y. Tomiyama,et al.  A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36) , 1990 .

[44]  Loise M. Francisco,et al.  Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.

[45]  L. Yesner,et al.  Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. , 1996, Blood.

[46]  J. Engelman,et al.  Palmitoylation of Caveolin-1 at a Single Site (Cys-156) Controls Its Coupling to the c-Src Tyrosine Kinase , 2001, The Journal of Biological Chemistry.

[47]  D. Steinberg,et al.  Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. , 1997, Circulation.

[48]  R. Silverstein,et al.  Lysosomal Integral Membrane Protein II Binds Thrombospondin-1 , 1998, The Journal of Biological Chemistry.

[49]  O. Volpert,et al.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.

[50]  H. Webster,et al.  Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. , 1991, The Journal of infectious diseases.

[51]  S. Hazen,et al.  Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. , 1999, The Journal of clinical investigation.

[52]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.